Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-08-20

FDA Approved: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

The FDA approved a supplemental application from Prasco Laboratories for the fixed-dose combination spironolactone and hydrochlorothiazide.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Spironolactone and Hydrochlorothiazide (Spironolactone; Hydrochlorothiazide)

Snippet

SUPPL AP for SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE)